Rimegepant: Effective Migraine Relief for Triptan-Sensitive Adults

Research Summary

In a groundbreaking study published in the journal Cephalalgia, researchers explored the efficacy of rimegepant as an acute migraine treatment for adults unsuitable for triptans. This phase 4 trial included 585 participants who either couldn't tolerate triptans or found them ineffective. Participants were given a single 75-mg dose of rimegepant or a placebo to treat migraines of moderate or severe intensity. The study showed that 55.9% of those on rimegepant experienced pain relief within 2 hours, compared to 32.7% on placebo, with all key secondary endpoints favoring rimegepant. The treatment was well-tolerated, with no severe adverse events reported, suggesting it as a promising alternative for those who cannot use triptans.

Study Details

📄 Title: Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.